News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Harmony Biosciences reported record quarterly growth for its narcolepsy treatment WAKIX, which supports further investment in its pipeline. The company is advancing BP-205, an orexin 2 receptor agonist, with promising early data and plans for multiple Phase II studies. Additionally, Harmony is progressing Phase …
Zacks Research has downgraded Harmony Biosciences (NASDAQ:HRMY) from a "strong buy" to a "hold" rating, aligning with the overall consensus. Despite the downgrade, Harmony Biosciences reported a strong quarter with EPS of $1.28 and revenue of $261.28 million, exceeding analyst expectations. The stock opened …
United States Antimony (NYSE: UAMY) saw its shares plunge 25% after reporting unfavorable Q2 revenue of US$7.9 million, down from US$10.5 million a year earlier, and slashing its full-year 2026 revenue guidance from US$125 million to a range of US$60 million to US$75 million. …
United States Antimony (UAMY) shares plummeted 25% after the company slashed its 2026 revenue guidance from $125 million to $60-75 million. This significant cut was driven by a collapse in antimony prices from $28 to $14 per pound, despite an increase in antimony pounds …
Sharemaestro market context Price below Trend Line 44 weeks -57.3% · Next-week setup negative 22.4%Key Points U.S. Antimony reported Q2 2026 financial results yesterday. The company failed to meet analysts' Q2 2026 revenue expectations.10 stocks we like better than United States Antimony › The dog days of summer are taking a bite out of United States Antimony(NYSE: UAMY) …
Sharemaestro market context Price below Trend Line 44 weeks -57.3% · Next-week setup negative 22.4%United States Antimony Corp. (UAMY) reported a 25% year-over-year revenue drop in Q2 2026 to $7.9 million, primarily due to a 52% decline in antimony prices, despite a 26% increase in sales volumes. The company revised its full-year 2026 revenue guidance down to $60 …
United States Antimony Corporation (UAMY) is facing significant downside pressure after slashing its fiscal 2026 revenue guidance to $60M–$75M from $125M, well below the Street's $115M consensus. This drastic reduction is attributed to weak antimony prices, delayed DLA contract deliveries, and slower production ramp-ups, …
United States Antimony Corporation Q2 2026 Earnings Call Summary - Moby Strategic Execution and Market Dynamics Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. …
Sharemaestro market context Price below Trend Line 44 weeks -57.3% · Next-week setup negative 22.4%HC Wainwright has lowered its price target for United States Antimony (NYSE:UAMY) to $9.25 from $11.75, while maintaining a "buy" rating, indicating a potential 40% upside. The stock currently holds a "Moderate Buy" consensus rating from analysts with an average price target of $8.42. …
United States Antimony (UAMY) experienced a significant 14% drop in premarket trading after reporting a sharp decline in Q2 sales. The company's Q2 revenue fell 24.7% year-over-year to $7.9M, missing analyst estimates by $13.77M. Consequently, the full-year 2026 revenue outlook was also cut.
United States Antimony Corp (UAMY) reported Q2 2026 earnings with a 25% year-over-year revenue decline to $7.9 million, primarily due to a 52% drop in antimony selling prices despite a 26% increase in antimony volumes sold. The company maintained a strong liquidity position of …
United States Antimony Corporation (USAC) reported its financial results for Q2 and the first six months of 2026. Revenues for Q2 were $7.9 million, with a net income of $0.1 million, driven by a 110% year-over-year increase in Zeolite revenues and a 26% increase …
This article reports on the filing of a Form 8K by United States Antimony Corp on August 11. The brief piece indicates that this SEC filing is relevant news for the stock markets, specifically mentioning the company's stock symbol UAMY. No further details about …
United States Antimony (UAMY) reported Q2 2026 revenue of $7.9 million and net income of $0.1 million, with an operating loss of $7.0 million. The company updated its full-year 2026 revenue guidance to $60 million–$75 million, down from $125 million, citing increased DLA deliveries …
United States Antimony (UAMY) reported a Q2 2026 revenue of $7.9 million, a decrease from $10.5 million year-over-year, with net income falling to $0.1 million. Despite the revenue drop, antimony pounds sold (excluding DLA) increased by 26% and zeolite revenue rose by 110%. The …
Search by ticker symbol or company name and select a result to open its chart.